FIT Biotech Oy
Company release October 3, 2016 at 9:00 am EET
Liquidity Providing agreement with S-Pankki to expire
The Liquidity Providing agreement of Mach 1, 2016 between S-Pankki Oy:n and FIT Biotech Oy will expire on October 30, 2016.
FIT Biotech agreed on Liquidity Providing with FIM Sijoituspalvelut Oy:n during the listing process to Nasdaq Helsinki Oy’s First North -marketplace in summer 2015. Liquidity providing agreement was transferred to S-Pankki Oy as of March 1, 2016 as part of the group’s internal business transaction.
FIT BIOTECH OY
Board of Directors
For further information:
Chairman of the Board of Directors Juha Vapaavuori
E-mail: juha.vapaavuori@fitbiotech.com
Tel: +358 50 372 0824
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
